m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01912)
Name
5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
Synonyms
CHEMBL583588; SCHEMBL5613483; BDBM50300472; 5-(4''-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H17NO3
InChI
1S/C18H17NO3/c19-12-14-3-8-16(9-4-14)15-6-1-13(2-7-15)5-10-17(20)11-18(21)22/h1-4,6-9,17,20H,5,10-11H2,(H,21,22)
InChIKey
YDAZWMGCTBJQEO-UHFFFAOYSA-N
PubChem CID
44626352
TTD Drug ID
D0K0YX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-12 (MMP-12)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-12 (MMP-12) is a therapeutic target for 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid through regulating the expression of Matrix metalloproteinase-12 (MMP-12). [1], [2]
Matrix metalloproteinase-13 (MMP-13)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-13 (MMP-13) is a therapeutic target for 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid through regulating the expression of Matrix metalloproteinase-13 (MMP-13). [4], [5]
References
Ref 1 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.
Ref 2 The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. doi: 10.1016/j.bmcl.2009.07.155. Epub 2009 Aug 6.
Ref 3 FTO promotes cell proliferation and migration in esophageal squamous cell carcinoma through up-regulation of MMP13. Exp Cell Res. 2020 Apr 1;389(1):111894. doi: 10.1016/j.yexcr.2020.111894. Epub 2020 Feb 6.
Ref 4 Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem Lett. 2010 Jan 15;20(2):576-80. doi: 10.1016/j.bmcl.2009.11.081. Epub 2009 Nov 22.
Ref 5 METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte. Biochem Biophys Res Commun. 2019 Aug 13;516(1):22-27. doi: 10.1016/j.bbrc.2019.05.168. Epub 2019 Jun 8.